UBS has given Sartorius a "Neutral" rating and a target price of 264 euros after the company released its third-quarter figures.
The laboratory services provider reported sales that were lower than expected, but operating profit was in line with expectations, according to analyst Matthew Weston.
The report suggests that Sartorius may have a positive outlook, especially due to a recovery in orders within the BPS division, which could have a positive impact on the market.